# Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

> **NCT01446744** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 99 (actual)

## Conditions studied

- Metastatic Tumors

## Interventions

- **RADIATION:** Stereotactic ablative radiotherapy
- **RADIATION:** palliative radiotherapy

## Key facts

- **NCT ID:** NCT01446744
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-11
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446744, "Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01446744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*